JPMorgan analyst Anupam Rama raised the firm’s price target on Ideaya Biosciences (IDYA) to $72 from $66 and keeps an Overweight rating on the shares. The firm also added Ideaya to its Analyst Focus List as a top growth idea. JPMorgan sees upside in the shares on the potential of darovasertib in uveal melanoma alone. This could drive the stock the mid-$30s to low-$40s across the spectrum of settings, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences’ Promising Potential with IDE849: Analyst Charles Zhu’s Buy Rating Ahead of WCLC 2025
- Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025
- Ideaya Biosciences initiated with a Buy at TD Cowen
- Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences
- Ideaya Biosciences resumed with a Neutral at Goldman Sachs